v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
9 Months Ended
May 31, 2026
May 31, 2025
Cash flows from operating activities    
Net income (loss) $ 8,786 $ (64,037)
Adjustments to reconcile net income (loss) to net cash provided by operating activities    
Depreciation and amortization 4,261 6,857
Change in fair value of contingent consideration 0 (640)
Discharge of holdback obligation related to Immunetrics acquisition 0 (224)
Amortization of investment premiums 7 (64)
Stock-based compensation 4,894 4,830
Deferred income taxes 606 (8,081)
Loss from disposal of assets 69 23
Impairments 0 77,221
Currency translation adjustments 15 (28)
(Increase) decrease in    
Accounts receivable (7,485) (5,644)
Prepaid income taxes 1,514 1,243
Prepaid expenses and other current assets (130) 274
Increase (decrease) in    
Accounts payable 1,764 1,061
Other liabilities 2,472 (2,600)
Deferred revenue 2,582 2,348
Net cash provided by operating activities 19,355 12,539
Cash flows from investing activities    
Purchases of property and equipment (139) (449)
Vendor refund related to property and equipment 310 0
Purchase of short-term investments (28,188) (6,500)
Proceeds from maturities of short-term investments 15,001 14,017
Proceeds from sales of investments 0 995
Purchased intangibles (11) (368)
Net working capital & excess cash settlement - Pro-ficiency acquisition 0 (227)
Capitalized computer software development costs (2,343) (2,115)
Net cash (used in) provided by investing activities (15,370) 5,353
Cash flows from financing activities    
Payments on contracts payable 0 (1,576)
Proceeds from the exercise of stock options 486 323
Net cash provided by (used in) financing activities 486 (1,253)
Net increase in cash and cash equivalents 4,471 16,639
Cash and cash equivalents, beginning of period 30,853 10,311
Cash and cash equivalents, end of period 35,324 26,950
Supplemental disclosures of cash flow information    
Income taxes paid 756 1,020
Supplemental disclosures of non-cash activities    
Measurement period adjustments 0 956
Non-cash investing and financing activities    
Right of use assets capitalized $ 47 $ 0